Abstract
Factor XI (fXI) and factor IX (fIX) are zymogens of plasma proteases that are required for normal formation and maintenance of a blood clot. Recent work has implicated these proteins in the pathogenesis of vascular thrombosis. Epidemiologic studies indicate that high levels (top 10% of normal distribution) of fXI or fIX are independent risk factors for venous thromboembolism, increasing risk ~2-fold. Recently, it was shown that fXI deficiency protects mice from carotid artery occlusion in a ferric chloride (FeCl3 ) injury model. FeCl3-induced thrombus formation involves thrombin generation, in addition to platelet activation and von Willebrand factor. We used a modified version of the FeCl3 model to study the antithrombotic effects of complete fXI or fIX deficiency. In wild type C57Bl/6 mice, carotid artery flow measured by Doppler flow probe is completely blocked within 10 minutes of applying 3.5% FeCl3 to the vessel. 3.0% FeCl3 induced occlusion in some (5 of 8) mice by 30 minutes, while no animal treated with 2.5% FeCl3 experienced occlusion. FXI and fIX deficient mice were fully protected from occlusion induced by 3.5% or 5% FeCl3. Some fXI (4 of 8) and fIX (4 of 6) deficient animals developed occlusion with 7.5% FeCl3, while occlusion occurred in all mice at 10% FeCl3. To put the effect of fXI or fIX deficiency on this model into perspective, it requires a very high dose of heparin (1000 U/kg) to produce similar protection. With 5% FeCl3, heparin at 200 U/kg only protects 50% of wild type mice from occlusion, despite prolonging the activated partial thromboplastin time beyond the upper limit of the assay (> 500 secs). High dose aspirin (100 mg/kg) did not prevent occlusion induced by 5% FeCl3, despite producing a nearly complete block of arachidonic acid-induced platelet aggregation in vitro. While fXI and fIX deficiency affect the FeCl3 model similarly, they have significantly different impacts on a tail bleeding time (TBT) assay. FXI deficient and wild type mice have similar mean TBTs (265 ± 68 and 287 ± 92 secs, respectively), while fIX deficiency causes prolonged bleeding (1561 ± 125 secs, p < 0.01). In comparison, heparin (200 units/kg) causes the TBT to exceed the upper limit of the assay (1800 seconds), while aspirin (30 mg/kg) modestly increases the TBT (~2.2-fold). The data indicate that fXI and fIX are involved in thrombus formation in the FeCl3 model, and support a growing body of evidence that thrombin formation through the fIX/fXI axis contributes to thrombotic disease. Given the mild bleeding diathesis associated with fXI deficiency, inhibition of fXI may be a useful component of therapy for treating or preventing thrombus formation, and would be associated with a relatively low risk of bleeding.
Author notes
Corresponding author